Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)
China · Delayed Price · Currency is CNY 5.04
-0.16 (-3.08%)
Jul 30, 2026, 3:00 PM CST
SHA:603669 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,658 | 3,208 | 3,694 | 3,988 | 4,140 | 7,204 | |
Market Cap Growth | -15.45% | -13.14% | -7.39% | -3.66% | -42.54% | 17.15% |
Enterprise Value | 3,819 | 3,301 | 3,626 | 3,740 | 3,720 | 6,568 |
Last Close Price | 5.20 | 4.56 | 5.25 | 5.53 | 5.74 | 9.84 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 109.32 |
Forward PE | - | 16.63 | 16.63 | 16.63 | 16.63 | 16.63 |
PS Ratio | 10.19 | 9.95 | 9.73 | 20.26 | 14.31 | 9.73 |
PB Ratio | 5.87 | 5.17 | 4.80 | 4.28 | 3.65 | 4.94 |
P/TBV Ratio | 6.90 | 6.09 | 5.52 | 4.85 | 4.06 | 5.41 |
P/FCF Ratio | - | - | - | - | - | 97.77 |
P/OCF Ratio | - | - | - | - | - | 56.07 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 10.64 | 10.24 | 9.55 | 19.00 | 12.86 | 8.87 |
EV/EBITDA Ratio | - | - | - | - | - | 84.39 |
EV/EBIT Ratio | - | - | - | - | - | 170.96 |
EV/FCF Ratio | - | - | - | - | - | 89.14 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.51 | 0.47 | 0.34 | 0.61 | 0.55 | 0.65 |
Debt / EBITDA Ratio | - | - | - | - | - | 11.64 |
Debt / FCF Ratio | - | - | - | - | - | 12.88 |
Net Debt / Equity Ratio | 0.26 | 0.20 | -0.03 | -0.18 | -0.30 | -0.42 |
Net Debt / EBITDA Ratio | -2.37 | -1.50 | 0.28 | 1.34 | 2.57 | -7.93 |
Net Debt / FCF Ratio | -1.05 | -0.91 | 0.18 | 2.76 | 3.16 | -8.37 |
Asset Turnover | 0.31 | 0.27 | 0.26 | 0.11 | 0.13 | 0.28 |
Inventory Turnover | 4.19 | 3.31 | 4.88 | 2.08 | 1.88 | 2.58 |
Quick Ratio | 0.94 | 0.89 | 2.43 | 3.30 | 3.51 | 2.62 |
Current Ratio | 1.15 | 1.10 | 2.68 | 3.63 | 3.74 | 2.76 |
Return on Equity (ROE) | -24.98% | -27.80% | -15.38% | -14.67% | -15.10% | 4.49% |
Return on Assets (ROA) | -4.87% | -5.73% | -4.74% | -6.11% | -5.06% | 0.92% |
Return on Invested Capital (ROIC) | -12.02% | -14.51% | -14.46% | -21.91% | -21.70% | 4.91% |
Return on Capital Employed (ROCE) | -14.10% | -17.20% | -10.50% | -12.30% | -11.40% | 2.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -4.69% | -6.02% | -3.54% | -3.80% | -4.73% | 0.92% |
FCF Yield | -4.17% | -4.23% | -3.24% | -1.53% | -2.64% | 1.02% |
Dividend Yield | - | - | - | - | - | 1.02% |
Payout Ratio | - | - | - | - | - | 241.58% |
Buyback Yield / Dilution | -1.29% | 1.48% | -0.77% | -0.17% | -0.18% | 5.75% |
Total Shareholder Return | -1.29% | 1.48% | -0.77% | -0.17% | -0.18% | 6.76% |